

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 June 2001 (28.06.2001)


(10) International Publication Number
WO 01/45585 A1

PCT

- (51) International Patent Classification⁷: A61C 8/00, 19/06
(21) International Application Number: PCT/IT00/00527
(22) International Filing Date:
18 December 2000 (18.12.2000)
(25) Filing Language: Italian
(26) Publication Language: English
(30) Priority Data:
FI99A000258 21 December 1999 (21.12.1999) IT
(71) Applicant (for all designated States except US): CON-
SIGLIO NAZIONALE DELLE RICERCHE [IT/TT];
Piazzale Aldo Moro, 7, I-00185 Roma (IT).
(72) Inventor; and
(75) Inventor/Applicant (for US only): CHIARELLI, Piero
[IT/TT]; Via Cantani 1B, I-56017 S. Giuliano Terme (IT).
(74) Agents: MANNUCCI, Michele et al.; Via della Scala, 4,
I-50123 Firenze (IT).
(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Published:
— With international search report.

[Continued on next page]

- (54) Title: DENTAL PROSTHESIS WITH MEANS FOR THE RELEASE OF ACTIVE SUBSTANCES**



(57) Abstract: The prosthetic structure for dental implants comprises a base material (13; 15; 17) incorporating at least one active component, the base material releases the active component in a controlled manner when the prosthetic structure is implanted in a living organism.

WO 01/45585 A1



— Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

DENTAL PROSTHESIS WITH MEANS FOR THE RELEASE OF ACTIVE SUBSTANCES

DESCRIPTION5 Technical field

The present invention relates to a prosthesis for dental implants that has the purpose of improving the outcome of an implantation procedure or of preventing the development of various kinds of complications following the implantation of a prosthetic structure.

10 State of the art

Failure of a dental implant can be caused by imperfect stabilization at the time of intervention, but also by phenomena of bone resorption that appear some time after implantation. Loss of alveolar bone tissue, which acts as a support for the dental implants, can occur for physiological reasons
15 connected with the patient's advanced age, or through necrosis following excessive compressive loading, which may be caused by inflammation and infections that originate on the surface of the gums and then advance, during their subsequent development, deeper and deeper towards the bone. The latter case can also occur even when surgical intervention has been executed
20 correctly and in sterile conditions for implantation, since gum infections can arise in the post-operative period.

In both situations, the end result is an increase of the processes of resorption of the bone matrix, which oppose the activity of new bone formation around the prosthesis. In this case the result is loss both of extracellular
25 matrix and of mineral component, as well as decrease in density and strength of the bone tissue.

Another possible cause of failure of a dental implant is the large difference in elastic modulus between bone (elastic modulus 17.4 GPa) and the titanium of which the prosthesis is made (the elastic modulus of which is
30 approx. 105 GPa, compared with 19.8 GPa of the tooth). This important difference in elasticity between prosthesis and bone has an adverse effect on the latter, when it is subjected to stresses, producing microtraumas and

- 2 -

micronecroses that tend to sclerotize the bone, weakening its mechanical structure, ultimately leading to mobility of the implant.

For the problems described above to be tackled effectively, it is important for the implantation zone to be protected constantly against the development of infections following the intervention, for stimulation of bone regrowth and its integration with the prosthesis as quickly as possible.

Summary of the invention

For solving the problems described above, the invention proposes a prosthetic structure for dental implants comprising a base material incorporating at least one active component, in which the base material releases the active component in a controlled manner when the prosthetic structure has been implanted in an organism.

According to a first embodiment, the base material is a polymeric material, for example a material with the characteristics of a hydrogel. The active component can in general be a drug and in particular a drug whose function is to prevent or cure any inflammations of the bone tissue and/or of the soft tissue, especially the gums. According to a particular embodiment, the active component can be an antibiotic.

According to another aspect of the invention, the active component can be a component that acts as a metabolic stimulator of bone growth. In this last case the component can be selected for example among the morphogenetic proteins, the biphosphonates, osteogenetic proteins and/or their combinations.

The hydrogel or other controlled-release base material containing the active component can be located in a "seating" made in the portion of the prosthetic structure intended to be implanted in the bone, for example in the apical zone. Alternatively or in combination, it is possible to provide a seating that is made in the zone of the prosthetic structure that comes into contact with the gingival zone. In the first case the active component will be, advantageously, a metabolic stimulator of bone regrowth and will facilitate the reconstruction of the bone tissue around the zone of the prosthetic structure in contact with the actual bone. In the second case the active component will

preferably be a drug with antibiotic action or the like, for preventing or curing the development of inflammations at the bone tissue level. In the second case the prosthetic structure can be of the type comprising a removable healing plug and the base material with the appropriate active component can be
5 located in a seating made in this healing plug and can be removed once the definitive prosthesis is fitted permanently.

According to another aspect of the present invention, a part at least of the internal portion of the prosthetic structure intended to be implanted in the bone has a coating consisting of a base material incorporating, for example, a
10 factor that has the function of a metabolic stimulator of bone regrowth. The coating can be made advantageously with a base material possessing an elastic modulus between 0.1 and 25 GPa and preferably between 0.5 and 1.5 GPa. The coating consists advantageously of a bioabsorbable base material, so that once implantation has been effected, the base material constituting
15 the coating of the portion of the prosthesis in contact with the bone is gradually resorbed, while around the prosthesis itself there is reconstruction of bone tissue.

According to a perfected, particularly advantageous embodiment of the invention, a coating formed from the base material surrounding, at least
20 partially, the internal portion of the prosthetic structure is loaded with microspheres of non-resorbable material. In this way the bone tissue that regrows following resorption of the base material will have a spongy, i.e. cellular, structure, corresponding to the non-resorbable microspheres. The microspheres can consist of a hydrogel or some other suitable material. The
25 active component can be contained in the non-bioabsorbable microspheres.

It is clear from the foregoing that the prosthetic structure according to the present invention permits the use of biocompatible hydrogels that permit continuous controlled release of suitable drugs such as antibiotics and/or metabolic stimulators respectively in the gingival zone and in the zone in
30 which the prosthesis is in contact with the bone.

In this connection, knowledge and techniques are now well consolidated in the field of biocompatible and/or bioresorbable polymeric

- 4 -

materials for the release and dosage of pharmacological substances in the human body, but the use of these products in dental prostheses for the purposes described above has not been proposed. A hydrogel suitable for use in the present invention is described in EP-A-0 058 497.

5 The dosages and the times for *in situ* release of the substances contained in the hydrogels can be controlled by suitably varying the porosity of said materials or the kinetics of resorption in the case of bioresorbable polymers.

10 A range of implantation devices can be assembled on the basis of the modular modifications according to the present invention, depending on the various requirements. The structural modifications that have been developed can be applied to a great many commercially-available prostheses, which have in general tackled, comprehensively and exhaustively, the problem of mechanical design and of purity of the material, but have not tackled the case
15 of pharmacological interaction with the surrounding system with which they will interact.

Brief description of the drawings

20 The invention will be better understood by following the description and the appended drawing, which shows a practical, non-limiting example of the said invention. In the drawing, the single diagram shows, in longitudinal section and partial view, a prosthetic structure according to the invention.

Detailed description of the preferred embodiment of the invention

25 A prosthetic structure of the type with a healing plug is shown in the diagram and is designated 1. The prosthetic structure has a body 3 defining an apical portion and intended to be implanted in the bone. The body 3 has a threaded stem 5 and a threaded internal hole 7. A threaded stem 9 of a healing plug 11 engages with hole 7. The healing plug is screwed into body 3 of the prosthetic structure 1 and is held in this position for the necessary time prior to its replacement with the upper portion of the prosthesis that replaces
30 the tooth.

 According to a first aspect of the present invention, near the apical extremity of the body 3 of the prosthetic structure 1, a seating 13 is provided,

- 5 -

in which a base material is inserted, for example a hydrogel, containing an active component, such as an antibiotic or a metabolic stimulator of bone regrowth. Bearing in mind that this prosthetic portion will be implanted in the bone tissue, it will be preferable to employ, as active component in this
5 seating, a metabolic stimulator of regrowth rather than a drug possessing an antibiotic function.

According to another aspect of the present invention, around an intermediate zone of portion 3 of the prosthetic structure 1, a coating 15 is provided, consisting of a base material, which can for example be the same
10 material inserted in seating 13, or a different material, but nevertheless having the function of continuous, controlled release of an active component which, also in this case, can be a stimulator of bone regrowth.

Microspheres of a non-bioabsorbable gel can be embedded in coating 15, made for example of a bioabsorbable gel. In this case the active
15 component can be embedded in one or the other of the two gels and preferably in the gel constituting the microspheres.

When the prosthetic structure has been implanted, the gradual release of the regrowth factor from the coating 15 and/or from the seating 13 facilitates reconstruction of the bone tissue. The latter regrows around the
20 body 3 of prosthetic structure 1 and comes to occupy the space progressively liberated by the bioabsorbable gel forming the coating 15. The possible presence of microspheres inside this coating leaves zones in which the bone tissue does not regrow, and hence assumes a porous structure. By suitably selecting the elastic modulus of the material constituting the microspheres, a
25 structure is obtained with optimum elasticity for correct functioning of the prosthesis.

In essence the coating 15 has a function of shock absorber between the prosthetic structure and the bone and limits bone traumas when the prosthesis is submitted to stresses, for example during mastication. This
30 coating makes it possible to solve the problems connected with absence of the periodontium, i.e. of the zone of the bone surrounding the tooth that is replaced in this case by the prosthetic structure. The periodontium has an

- 6 -

elastic modulus of the order of 0.8 GPa and so is softer than true bone (elastic modulus 17 GPa) and tooth (19.8 GPa).

5 The coating 15 made with a suitable elastic modulus and with a thickness between for example 1 and 500 microns, makes it possible to eliminate the problems arising from the difference in elastic modulus between the titanium of the prosthetic structure and the actual bone. When, as mentioned above, the coating is made of a hydrogel or some other bioresorbable material loaded with non-resorbable microspheres, the residual microspheres permit reconstruction of the tissue of the spongy tissue that
10 accordingly creates an interface between the prosthetic structure and the pure bone, with a shock-absorbing behavior very similar to that of the natural periodontium.

The coating 15 can also be made with a material with a suitable elastic modulus and thickness for constituting a long-lasting shock-absorbing layer.
15 In this case it is preferably constituted of a non-bioresorbable material. If its only function is shock absorbing, it will not contain any active component to be released once the prosthesis is implanted. In this case the coating 15 can be used alone or in combination with a base material that releases an active component disposed at other points of the prosthesis, as described in this
20 context.

According to a third aspect of the present invention, in the upper zone of the prosthetic structure 1 consisting in the present case of the healing plug 11, another seating 17 is provided for receiving a base material, for example a hydrogel, loaded with an active component that is gradually released. In the
25 example illustrated, the seating 17 has an annular development and has holes 17A by which the interior of the seating 17 communicates with the surrounding gingival tissues once the prosthetic structure has been implanted. The active component loading the base material contained in seating 17 is released in a gradual and controlled manner through the holes 17A. This
30 active component can consist of an anti-inflammatory drug, an antibiotic, and/or of stimulators of tissue regrowth. The holes 17A are of a suitable size, and preferably larger than 0.3 mm and are arranged laterally all the way along

the annular development of the healing plug 11.

The prosthetic structure shown in the drawing has both the seating 13 in the zone intended to be implanted in the bone, and the seating 17 in the outer zone of the prosthesis, as well as the coating 15. It should, moreover, be understood that these three aspects can also be used individually or in combination two by two.

For each of the three applications it is possible to use hydrogels of various kinds as well as active components of various types according to the specific application.

10 In the seating 17 of the healing plug 11 it is possible to insert a hydrogel based on polyvinyl alcohol (PVA) incorporating an antibiotic, or equivalent active component, for example metronidazole.

15 In the seating 13 made in the apical zone of the body 3 of the prosthesis it is moreover possible to use a hydrogel based on polyvinyl alcohol but advantageously replacing the metronidazole with a bone regrowth factor such as the "bone morphogenetic proteins" (BMP), i.e. bone morphogenetic proteins, or other active components possessing similar functions such as bisphosphonates, osteogenetic proteins or other components possessing bone tissue stimulation function.

20 For the seating 15 made around a zone of the body 3 of the prosthesis it is possible to use polylactic acid in conjunction with amelogenin for stimulation of regrowth of the periodontal ligament during spontaneous resorption of the polylactic acid. Alternatively, as mentioned above, the polylactic acid can be loaded with microspheres of non-resorbable hydrogels containing stimulators of bone regrowth. Replacement of the polylactic acid in the spaces around the microspheres with bone tissue tends to create an elastically yielding alveolar bone structure and we thus obtain a lowering of the level of total load on the bone tissue surrounding the prosthesis during the torsional stresses exerted for example during mastication. In both cases the objective is to create a cushioned zone between the prosthetic structure and the bone with shock absorbing function.

30 It is to be understood that the drawing only shows one example given

- 8 -

purely as practical demonstration of the invention, it being possible for this invention to vary in its forms and arrangements but without leaving the scope of the concept taught by the said invention.

CLAIMS

1. A prosthetic structure for dental implants comprising a base material incorporating at least one active component, wherein said base material releases said active component in a controlled manner when said
5 prosthetic structure has been implanted in a living organism.
2. A prosthetic structure for dental implants containing a seating for the insertion of a material incorporating at least one active component for the controlled release of said active component in a living organism when said prosthetic structure has been implanted in said organism.
- 10 3. Prosthetic structure as in Claim 1 or 2, wherein said base material is a polymeric material.
4. Prosthetic structure as in Claim 3, wherein said material is a polymeric material with the characteristics of a hydrogel.
5. Prosthetic structure as in one or more of the preceding claims,
15 wherein said at least one active component is an antibiotic.
6. Prosthetic structure as in Claim 5, wherein said active component is metronidazole.
7. Prosthetic structure as in one or more of the preceding claims, wherein said active component is a metabolic stimulator of bone regrowth.
- 20 8. Prosthetic structure as in Claim 7, wherein said active component is selected from the group comprising: morphogenetic proteins, bisphosphonates, osteogenetic proteins, amelogenin, or their combinations.
9. Prosthetic structure as in one or more of the preceding claims, comprising an internal portion intended to be implanted in the bone, there
25 being provided in said internal portion a seating with an opening to the outside of the prosthesis for locating said base material.
10. Prosthetic structure as in one or more of the preceding claims, comprising an outer portion intended to come into contact with the gingival zone, there being provided in said outer portion a seating with an opening to
30 the outside of the prosthesis for locating said base material.
11. Prosthetic structure as in Claim 10, wherein said outer portion includes a removable healing plug.

12. Prosthetic structure as in one or more of the preceding claims, including an inner portion intended to be implanted in the bone, there being applied on at least one zone of said inner portion, a coating consisting of said base material.

5 13. Prosthetic structure as in Claim 12, wherein said coating consists of a material possessing an elastic modulus between 0.1 and 25 GPa and preferably between 0.5 and 1.5 GPa.

14. Prosthetic structure as in Claim 12 or 13, wherein said coating consists of a bioresorbable material.

10 15. Prosthetic structure as in Claim 14, wherein said coating is loaded with microspheres of non-bioresorbable material.

16. Prosthetic structure as in Claim 15, wherein said microspheres consist of a hydrogel.


15 17. Prosthetic structure as in Claim 15 or 16, wherein the active component is contained in said microspheres.

17. Prosthetic structure including a portion intended to be implanted in the bone, characterized in that a coating consisting of a material possessing a shock absorbing function is applied to at least one zone of said inner portion.

20 18. Prosthetic structure as in Claim 17, characterized in that said material is a polymeric material possessing an elastic modulus between 0.1 and 25 GPa and preferably between 0.5 and 1.5 GPa, said polymeric material being substantially non-bioresorbable.

1 / 1

FIG. 1



INTERNATIONAL SEARCH REPORT

International Application No

PCT/IT 00/00527

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61C8/00 A61C19/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61C A61J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-------------------------|
| X | WO 97 22308 A (SCHUG JENS ;SUHONEN JOUKO (CH)) 26 June 1997 (1997-06-26) page 8, line 14-30 page 10, line 1-12 page 9, line 25-33 figure 18 | 1-3,5, 7-9,12, 14 |
| X | EP 0 864 299 A (STIFTUNG FÜR KLINISCHE FORSCHUNG ZUR FÖRDERUNG DER ORALEN GESUNDHEIT) 16 September 1998 (1998-09-16) column 1, line 3-10,36-44 column 2, line 3-10,22-26,53-56 column 3, line 4-15 figures 7,7A --- -/-- | 1-3,5,7, 10,11 |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

12 April 2001

Date of mailing of the international search report

23/04/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Chabus, H

INTERNATIONAL SEARCH REPORT

In .ational Application No

PCT/IT. 00/00527

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| X | US 5 584 688 A (SAKUMA SHUJI ET AL) 17 December 1996 (1996-12-17) column 2, line 18-20 column 3, line 12-20,53-58 column 7, line 66 -column 8, line 3 figure 1 --- | 1,2,9,10 |
| X | NL 9 500 256 A (LEUVEN K U RES & DEV) 2 September 1996 (1996-09-02) page 4, column 10-34 page 6, line 11-21 figures 1-3 --- | 17,18 |
| X | WO 92 17127 A (LUMICISI FABRIZIO ;ROESLER FRANZ ROBERTO (IT)) 15 October 1992 (1992-10-15) page 2, line 1-9 page 3, line 7-19 figures ----- | 17 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IT 00/00527

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|---|--|
| WO 9722308 | A | 26-06-1997 | AU 1369297 A BR 9612051 A EP 0893975 A JP 2000501966 T US 6132214 A | 14-07-1997 09-02-1999 03-02-1999 22-02-2000 17-10-2000 |
| EP 0864299 | A | 16-09-1998 | NONE | |
| US 5584688 | A | 17-12-1996 | AU 677472 B AU 1019695 A CA 2134540 A DE 4432831 A FR 2717698 A GB 2287651 A IT MI950080 A, B JP 8010337 A | 24-04-1997 05-10-1995 23-09-1995 28-09-1995 29-09-1995 27-09-1995 22-09-1995 16-01-1996 |
| NL 9500256 | A | 02-09-1996 | NONE | |
| WO 9217127 | A | 15-10-1992 | IT 1244668 B | 08-08-1994 |